A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections

This study looks at the difference between XF-73 and placebo in reducing the carriage of a bacteria S. aureus in the nose before, during and after heart surgery. Only people who normally have S.aureus in their nose will be enrolled onto the study. This will be confirmed by analysis of a nasal swab (a cotton bud placed in the nose) before entering the study. It is expected 125 people will participate in this study. Participation will be confirmed by analysis of a nasal swab (a cotton bud placed in the nose) before entering the study. XF-73 or placebo will be given 5 times, with an equal chance of participants receiving either XF-73 or placebo. During the hospital stay more nasal swabs will be taken to determine the amount of S.aureus present in the participant's nose. Other tests such as blood samples, blood pressure and an examination of the nose and sense of smell will be performed as part of the safety assessment. After the hospital stay participants will be followed up for 30 days or if a device has been inserted into the body as part of the surgery for 90 days to look at the rates of post-operative infection between the placebo and XF-73 groups. The study will run for about 18 months. During this period, an independent data monitoring committee will review the study to make sure that the balance of benefits and risks of participating in the study does not change.

开始日期2019-08-29

申办/合作机构

Destiny Pharma Plc

NCT02282605 / Completed临床1/2期

A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects.

Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus aureus.

开始日期2014-09-01

申办/合作机构

Destiny Pharma Plc

NCT01592214 / Completed临床1期IIT

A Two-Part Phase I Study to Establish and Compare the Safety and Local Tolerability of Two Nasal Formulations of XF-73 for Decolonization of Staphylococcus Aureus: A Previously Investigated 0.5 mg/g Viscosified Gel Formulation Versus a Modified Formulation

This is a Phase I, multi-center, clinical study of XF-73 to evaluate the local (nasal) safety and tolerability of a modified, thinner lower viscosity formulation of intranasal XF-73 in healthy male and female subjects. In addition, the potential for systemic absorption of XF-73 in the modified, thinner lower viscosity and the previously investigated thicker, higher viscosity formulations and their decolonization efficacy in comparison to placebo will be evaluated. Both parts of the study will be double-blinded and Part 2 will also be placebo-controlled. Primary objective is to establish the safety and tolerability of two concentrations of a modified thinner, lower viscosity nasal formulation of XF-73 and to compare them to a previously investigated, thicker, higher viscosity formulation

开始日期2012-08-01

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与 Exeporfinium Chloride 相关的临床结果

登录后查看更多信息

100 项与 Exeporfinium Chloride 相关的转化医学

登录后查看更多信息

100 项与 Exeporfinium Chloride 相关的专利（医药）

登录后查看更多信息

项与 Exeporfinium Chloride 相关的文献（医药）

2023-07-01·Infection control and hospital epidemiology

Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study.

Article

作者: Milewski, Rita K C ; Rhys-Williams, William ; Dane, Aaron ; Firstenberg, Michael S ; Mangino, Julie E ; Love, William G ; Gonzalez Moreno, Jesus ; Lees, James P

We studied 83 cardiac-surgery patients with nasal S. aureus carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a S. aureus nasal carriage reduction of 2.5 log₁₀ with XF-73 compared to 0.4 log₁₀ CFU/mL for those who received placebo (95% CI, -2.7 to -1.5; P < .0001).

2023-01-01·Frontiers in cellular and infection microbiology

Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates.

Article

作者: Galvin, Helen Marie ; Love, William Guy ; Rhys-Williams, William

XF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative with rapid, potent bactericidal properties and a low propensity for engendering bacterial resistance. It is being developed clinically for the decolonization of Staphylococcus aureus in the nasal cavity to prevent post-operative staphylococcal infections. This study reports the minimum inhibitory concentration (MIC) of XF-73 in comparison to 22 antibiotics against a panel of >2,500 clinical isolates composed of 16 different Coagulase-positive and -negative Staphylococcus species from 33 countries. XF-73 was found to be effective against all isolates tested, with MICs ranging between ≤0.12 - 4 µg/ml (MIC₅₀ and MIC₉₀ values of 0.5 and 1 µg/ml respectively). XF-73 was found to be equally effective against antibiotic resistant isolates as antibiotic sensitive isolates, with no impact of pre-existing antibiotic resistance mechanisms to cell wall synthesis inhibitors (β-lactams, carbapenems, glycopeptides and cephalosporins), protein synthesis inhibitors (oxazolidinones, macrolides and tetracyclines), DNA synthesis inhibitors (fluoroquinolones) and a folate synthesis inhibitor. The panel selected also included examples of multidrug-resistant S. aureus isolates and, in all cases, the XF-73 MIC ranges were found to be similar against each of these groups. This dataset expands the knowledge of the breadth of activity of this novel antibacterial against a wide range of global S. aureus isolates and supports the potential utility of XF-73 for the treatment of patients who are S. aureus nasal carriers. Similar results were also obtained for multidrug-resistant isolates of other Staphylococcus species included in the study and collectively support the continued clinical development of XF-73 as an effective anti-staphylococcal drug.

2023-01-01·Frontiers in fungal biology

Antimicrobial effects of XF drugs against Candida albicans and its biofilms.

Article

作者: Williams, D W ; Hynes, D ; Love, W G ; Rhys-Williams, W ; Board-Davies, E L

Compared with antibiotics for treating bacterial infections, there are a limited number of antifungal agents. This is due to several factors, including the difficulties of identifying suitable antifungals that target the fungal cell without damaging host cells, and the reduced rates of diagnosis of fungal infections compared with those caused by bacteria. The problem of treating fungal infections is exacerbated by an increasing incidence of antifungal resistance among human fungal pathogens. Three XF drugs (XF-73, XF-70, and DPD-207) have previously displayed innate bactericidal effects and a low propensity for microbial resistance, with XF-73 and XF-70 having a second, light-activated mechanism of action [known as photodynamic therapy (PDT)]. In an effort to expand the repertoire of antifungal agents, this research assessed the in vitro activity of XF drugs via both mechanisms of action against six strains of the fungal pathogen Candida albicans in both planktonic and biofilm cultures. In addition, this research examined the effects of XF drug treatment on biofilms of C. albicans in a reconstituted human oral epithelium model. All C. albicans strains tested were susceptible to XF-73 and XF-70, with minimum inhibitory concentrations (MICs) between 0.25 µg/mL and 2 µg/mL; DPD-207 was less potent, with MICs between 4 µg/mL and 16 µg/mL, and light activation did not enhance these MICs. Complete biofilm eradication was not reported at the tested XF drug concentrations. However, live and dead staining of C. albicans cells in biofilms after XF drug treatment demonstrated that XF-73 and XF-70 were active against most Candida biofilms tested from 64 µg/mL; again, light activation did not enhance anti-biofilm activity. Candida biofilms were more resistant to DPD-207, with fungicidal effects occurring from 256 µg/mL. XF-73 and XF-70 reduced penetration of C. albicans biofilm into reconstituted human oral epithelium (RHOE) and resulted in less damage (as determined by reduced lactate dehydrogenase release) than untreated biofilms. Overall, the results highlight the potential of XF drugs as new drugs for the management of topical infections caused by C. albicans. Further studies are warranted on the development of XF drugs as antifungals, particularly for XF-73 and XF-70.

项与 Exeporfinium Chloride 相关的新闻（医药）

2024-07-15

·FierceBiotech

Destiny goes private to stay afloat after no partner found for anti-infection drug

Like many biotechs, Destiny has struggled on the public markets in recent years. Destiny Pharma’s search for a partner to take its nasal infection prevention med into phase 3 has come up short, leading the British biotech to go private to avoid liquidation. Destiny was one of the few biotechs to choose to list in London in recent years, joining the AIM exchange via a £15.3 million ($19.8 million at the time) offering in 2017. The Brighton, U.K.-based company’s pitch was to use the money to fund the phase 2b trial of XF-73, a nasal drug designed to prevent post-surgery staphylococcal infections. That trial read out in 2021, showing that XF-73 Nasal—a synthetic dicationic porphyrin drug called exeporfinium chloride—produced a more than 99% reduction in nasal bacterial load when compared to placebo, hitting the study’s primary endpoint. But the biotech has struggled to find a partner to take the asset into phase 3 development. With money tight, Destiny has been advised that its best chance of getting an infusion of equity is to return to being a private company. “While there can be no guarantee, the board believes that the only viable option now available to Destiny Pharma to create future shareholder value is the pursuit of capital as a private company,” Nigel Rudd, chair of Destiny’s board of directors, explained in a July 15 release. “Without taking this route, we believe that liquidation of the company is the most likely alternative,” Rudd added. Destiny entered 2024 with £6.4 million ($8.3 million) in cash and equivalents, and notified investors as far back as April that despite engaging with “a number of potential partners” and receiving “some strong and positive feedback” about XF-73 Nasal, the company had been unable to nail down a licensing partner. One stumbling block for potential partners was the anticipated phase 3 trial costs, as well as the general view that antibiotics have limited commercial potential, Destiny explained at the time. To this end, the company pledged to work to “enhance the attractiveness” of XF-73 with a new trial design that should halve the clinical costs. Despite the best efforts of CEO Chris Tovey, who moved across to Destiny from Jazz Pharmaceuticals in September 2023, to “vigorously pursue a potential licensing deal,” there is still no partner in sight. “Although we continue to speak to partners about this renewed proposition, we are extremely disappointed that a deal has not been forthcoming and, given our shortening cash runway, have been forced to amend our strategy as we seek to continue to progress this important product,” Tovey said in this morning’s release. Like many biotechs, Destiny has struggled on the public markets in recent years. The company’s stock rested comfortably above the one pound mark in 2021, but has declined since and despite a rally towards the end of 2023, now sits at just two pence per share. Destiny will put its delisting proposal to shareholders at a meeting later in July.

临床3期临床2期引进/卖出

2024-04-25

·FierceBiotech

Destiny calls time on SporeGen COVID collab, while Santhera hands lonodelestat back to Spexis

Destiny’s biggest concern right now is finding someone to help take forward XF-73. Both Destiny Pharma and Santhera Pharmaceuticals used their earnings announcements this morning to explain why a tighter clinical focus will come at the expense of one of their potential assets. In Destiny’s case, the company has decided not to extend its collaboration with SporeGen past the pre-agreed conclusion point this month. The two British biotechs had been working on a nasal spray of Bacillus bacteria that could work as a preventive treatment for COVID-19. The phase 1 candidate, dubbed SPOR-COV, has already been shown by SporeGen to provide 100% protection in preclinical models of influenza, according to Destiny’s website. But Destiny confirmed today that it would not be taking the collaboration any further as it “focus[es] resources on development of the XF platform and our other key company pipeline programs.” Destiny’s biggest concern right now is finding someone to help take forward XF-73, an antibiotic designed to prevent post-surgery infections. “The company has engaged with a number of potential partners and has received some strong and positive feedback on XF-73 nasal,” Destiny explained in the earnings release. “However, no potential licensing deal has, to date, been forthcoming that we believe would provide fair value to the company and its shareholders.” One stumbling block for potential partners are the anticipated phase 3 trial costs, as well as the general view that antibiotics have limited commercial potential, according to Destiny. To this end, the company is working to “enhance the attractiveness” of XF-73 with a new trial design that should halve the clinical costs. Destiny will also review “strategic options” for the asset, although at the moment these won’t stretch to putting the whole company up for sale. “XF-73 nasal has enormous market potential and can make a huge difference in the prevention of surgical site infections, and the reduction in the usage of antibiotics,” said CEO Chris Tovey in the release. “Whilst we will now be presenting an enhanced proposition for the product to potential partners, we also have initiated a wider review to evaluate a range of strategic options to progress the programme and to maximise value from XF-73 nasal,” Tovey added. In the case of Santhera, the writing was already on the wall for the lung disease candidate lonodelestat long before the Swiss biotech finally pulled the plug. Back in 2022, the company was already warning that available resources were being channeled to its Duchenne muscular dystrophy prospect vamorolone, leaving lonodelestat’s prospects dependent on finding fresh funding from somewhere. While the vamorolone dream became a reality when Santhera scored FDA approval last year, lonodelestat was left to languish. Focusing on the DMD drug, rebranded as Agamree, means Santhera has no time for lonodelestat. With internal development of the human neutrophil elastase inhibitor still on pause, Santhera finally confirmed in this morning’s earnings release that it is terminating work completely and will return lonodelestat to fellow Swiss biotech Spexis. “This has no further financial impact on the 2023 accounts, as an impairment was already recognized under development costs in the 2022 consolidated income statement,” Santhera pointed out.

临床1期上市批准

2023-02-24

·FierceBiotech

Destiny seals C. diff therapy's phase 3 fate with Sebela

Destiny Pharma CEO Neil Clark said a deal with Sebela Pharmaceuticals is in line with the company’s strategy to find partner companies to take their lead assets into late-stage development. Destiny Pharma could be in line for $570 million thanks to a new co-development agreement with U.S.-based Sebela Pharmaceuticals for a Clostridium difficile treatment. The two companies have agreed to work on NTCD-M3 together, with Sebela offering $1 million upfront, development milestones of $19 million and revenue-based milestones of up to $550 million, according to a Friday press release. Royalties are also included. Sebela will gain the North American rights to the treatment and lead and finance clinical development and commercialization activities in the region. U.K.-based Destiny will retain rights in Europe and the rest of the world and will complete ongoing manufacturing of clinical trial supplies for an upcoming phase 3 study. NTCD-M3 is Destiny’s lead asset under development to prevent C. difficile infection recurrence and was in-licensed in 2020. The therapy is an oral formulation of NTCD-M3 spores and protects the gut from the proliferation of toxic strains of C. difficile. A phase 3 study is expected to start in 2024, according to the release. Destiny’s CEO Neil Clark said the deal is in line with the company’s strategy to find partner companies to take their lead assets into late-stage development and reduce funding requirements. Meanwhile, Destiny used the opportunity to announce a fundraising of up to 8 million pounds sterling ($9.5 million) consisting of a placing, subscription and an open offer. The funds will help Destiny complete the required phase 3 work for NTCD-M3 as well as prep XF-73 Nasal for a phase 3 study. The treatment is being developed for preventing post-surgical staphylococcal hospital infections including MRSA.

临床3期引进/卖出

100 项与 Exeporfinium Chloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Exeporfinium Chloride	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
术后感染	临床2期	美国	Destiny Pharma Plc	2019-08-29
术后感染	临床2期	格鲁吉亚	Destiny Pharma Plc	2019-08-29
术后感染	临床2期	塞尔维亚	Destiny Pharma Plc	2019-08-29
手术伤口感染	临床2期	美国	Destiny Pharma Plc	2019-08-29
手术伤口感染	临床2期	格鲁吉亚	Destiny Pharma Plc	2019-08-29
手术伤口感染	临床2期	塞尔维亚	Destiny Pharma Plc	2019-08-29
葡萄球菌感染	临床2期	美国	Destiny Pharma Plc	2019-08-29
葡萄球菌感染	临床2期	格鲁吉亚	Destiny Pharma Plc	2019-08-29
葡萄球菌感染	临床2期	塞尔维亚	Destiny Pharma Plc	2019-08-29
金黄色葡萄球菌感染	临床2期	英国	Destiny Pharma Plc	2014-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03915470 (CTgov)	临床2期	手术伤口感染 \| 术后感染 \| 葡萄球菌感染	124	XF-73 (XF-73)	齋窪襯範襯選積衊淵齋(鏇鬱夢鹹艱構鑰觸膚餘) = 顧膚壓獵範餘網蓋襯獵繭餘淵鹽糧齋衊鹽窪壓 (顧鏇網蓋鑰選網鹹襯壓, 鑰鹹衊鬱廠淵夢醖齋鬱 ~ 遞簾淵鹽齋顧膚艱鬱膚) 更多	-	2022-06-01
				Placebo (Placebo)	齋窪襯範襯選積衊淵齋(鏇鬱夢鹹艱構鑰觸膚餘) = 蓋繭構齋廠餘遞築廠齋繭餘淵鹽糧齋衊鹽窪壓 (顧鏇網蓋鑰選網鹹襯壓, 齋憲鑰鹹鹽範廠觸簾簾 ~ 鏇鹹糧膚選夢窪積願憲) 更多
NCT01592214 (Pubmed \| J Glob Antimicrob Resist) 人工标引	临床1期	金黄色葡萄球菌感染	60	XF-73	築鹹淵構構顧積鏇醖膚(遞願網顧艱遞蓋繭鏇艱) = 窪鬱鹽襯憲簾膚構簾鹹鏇鏇襯獵淵築壓淵製廠 (願鹹鑰膚膚鏇顧鹹積淵 )	积极	2020-06-01
NCT02282605 (CTgov)	临床1/2期	金黄色葡萄球菌感染	60	Chlorhexidine gluconate 2% topical cloths+XF-73 nasal gel (XF-73 2.0 mg/g Nasal Gel)	鏇齋選鏇鏇遞觸餘鏇壓(膚襯鹽積夢築蓋艱獵構) = 築願範築製窪築醖憲襯鏇壓夢網繭鏇築糧齋廠 (遞選構遞顧獵鑰醖構構, 醖遞廠衊鹽廠齋積餘艱 ~ 糧簾築窪築廠齋鏇積願) 更多	-	2016-10-07
				Chlorhexidine gluconate 2% topical cloths+XF-73 nasal gel (XF-73 0.5 mg/g Nasal Gel)	鏇齋選鏇鏇遞觸餘鏇壓(膚襯鹽積夢築蓋艱獵構) = 繭鹹顧鬱網網淵夢齋繭鏇壓夢網繭鏇築糧齋廠 (遞選構遞顧獵鑰醖構構, 積壓鹹膚膚繭顧糧鹹觸 ~ 積鹹構醖鏇壓餘憲願鹽) 更多